drugset / Trial / NCT00265967
Irbesartan in Hypertension
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Study objectives: * To demonstrate the effect of irbesartan on the regulation of diastolic blood pressure, in case of missing one dose after a period of administration for 6 to 8 weeks * To evaluate the safety of irbesartan
Timeline
- Start
- 2005-09
- Primary completion
- 2007-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irbesartan | Small molecule | 150 mg | — |
| Subject | Irbesartan | Small molecule | 300 mg | — |